{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T21:58:50Z","timestamp":1769291930669,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11945-9","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:36:05Z","timestamp":1766129765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interim efficacy and safety analysis of the regimen containing delamanid in the treatment of multidrug resistant\/rifampicin-resistant\/extensively drug-resistant tuberculosis: a single-arm, prospective, monocentric, observational study"],"prefix":"10.1186","volume":"26","author":[{"given":"Yao","family":"Qin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingshan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"11945_CR1","volume-title":"Global tuberculosis report 2023","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023."},{"key":"11945_CR2","volume-title":"Global tuberculosis report 2024","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization; 2024."},{"key":"11945_CR3","doi-asserted-by":"crossref","unstructured":"H\u00e4cker B, Sch\u00f6nfeld N, Krieger D, Otto-Knapp R, Hittel N, Pflugmacher P, Bauer T. Long-term safety and tolerability of delamanid-containing regimens in MDR- and XDR-TB patients in a specialised tuberculosis treatment center in Berlin, Germany. Eur Respir J. 2020 Jul;6:2000009.","DOI":"10.1183\/13993003.00009-2020"},{"key":"11945_CR4","doi-asserted-by":"crossref","unstructured":"Mok J, Kang H, Koh WJ, Jhun BW, Yim JJ, Kwak N, Lee T, Kang B, Jeon D. Final treatment outcomes of delamanid-containing regimens in patients with MDR-\/XDR-TB in South Korea. Eur Respir J. 2019;54(5).","DOI":"10.1183\/13993003.00811-2019"},{"key":"11945_CR5","doi-asserted-by":"publisher","first-page":"1701105","DOI":"10.1183\/13993003.01105-2017","volume":"50","author":"L Kuksa","year":"2017","unstructured":"Kuksa L, Barkane L, Hittel N, et al. Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens. Eur Respir J. 2017;50:1701105.","journal-title":"Eur Respir J"},{"issue":"2","key":"11945_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/jac\/dkx373","volume":"73","author":"J Mok","year":"2018","unstructured":"Mok J, Kang H, Hwang SH, Park JS, Kang B, Lee T, Koh WJ, Yim JJ, Jeon D. Interim outcomes of Delamanid for the treatment of MDR- and XDR-TB in South Korea. J Antimicrob Chemother. 2018;73(2):503\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"11945_CR7","first-page":"e01202","volume":"65","author":"X Wang","year":"2021","unstructured":"Wang X, Mallikaarjun S, Gibiansky E. Population Pharmacokinetic analysis of Delamanid in patients with pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2021;65(1):e01202\u201320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"11945_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40249-021-00819-2","volume":"10","author":"J Gao","year":"2021","unstructured":"Gao J, Du J, Wu G, et al. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in china: focus on the safety. Infect Dis Poverty. 2021;10(1):32.","journal-title":"Infect Dis Poverty"},{"issue":"10","key":"11945_CR9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40264-015-0316-6","volume":"38","author":"MN Niemeijer","year":"2015","unstructured":"Niemeijer MN, van den Berg ME, Eijgelsheim M, Rijnbeek PR, Stricker BH. Pharmacogenetics of Drug-Induced QT interval prolongation: an update. Drug Saf. 2015;38(10):855\u201367.","journal-title":"Drug Saf"},{"issue":"2","key":"11945_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jelectrocard.2013.12.002","volume":"47","author":"AF Manini","year":"2014","unstructured":"Manini AF, Stimmel B, Vlahov D. Racial susceptibility for QT prolongation in acute drug overdoses. J Electrocardiol. 2014;47(2):244\u201350.","journal-title":"J Electrocardiol"},{"key":"11945_CR11","unstructured":"World Health Organization.WHO Consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment Geneva. World Health Organization; 2020."},{"issue":"10","key":"11945_CR12","first-page":"1025","volume":"41","author":"Chinese Antituberculosis Association","year":"2019","unstructured":"Chinese Antituberculosis Association. Guidelines for chemotherapy of drug-resistant tuberculosis (2019 short version). Chin J Antituberculosis. 2019;41(10):1025\u201373.","journal-title":"Chin J Antituberculosis"},{"key":"11945_CR13","unstructured":"U.S. Department of health and human services, national institutes of health, national institute of allergy and infectious diseases, division of AIDS. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, Corrected Version 2.1. 2017. [2021-01-31]. https:\/\/rsc.niaid.nih.gov\/clinical-research-sites\/daids-adverse-event-grading-tables"},{"issue":"23","key":"11945_CR14","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","volume":"366","author":"MT Gler","year":"2012","unstructured":"Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151\u201360.","journal-title":"N Engl J Med"},{"key":"11945_CR15","unstructured":"World Health Organization. The use of Delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. WHO\/HTM\/TB\/2014.23. Geneva. World Health Organization; 2014."},{"issue":"Suppl 1","key":"11945_CR16","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1016\/j.ijid.2022.02.043","volume":"124","author":"MJ Nasiri","year":"2022","unstructured":"Nasiri MJ, Zangiabadian M, Arabpour E, Amini S, Khalili F, Centis R, D\u2019Ambrosio L, Denholm JT, Schaaf HS, van den Boom M, Kurhasani X, Dalcolmo MP, Al-Abri S, Chakaya J, Alffenaar JW, Akkerman O, Silva DR, Mu\u0148oz-Torrico M, Seaworth B, Pontali E, Saderi L, Tiberi S, Zumla A, Migliori GB, Sotgiu G. Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. Int J Infect Dis. 2022;124(Suppl 1):S90\u2013103.","journal-title":"Int J Infect Dis"},{"key":"11945_CR17","doi-asserted-by":"crossref","unstructured":"Kwonjune J, Seung P, Khan MF, Franke S, Ahmed S, Aiylchiev M, Alam FA, Putri M, Bastard W, Docteur G, Gottlieb C, Hewison S, Islam L, Oyewusi M, Rich S, Wanjala A, Yedilbayev. Helena Huerga, Carole D Mitnick, for the endTB study group, culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis, Clin Infect Dis. 2020 15 July;71(2):415\u2013418.","DOI":"10.1093\/cid\/ciz1084"},{"key":"11945_CR18","doi-asserted-by":"crossref","unstructured":"Marwah V, Patil PR, Choudhary R, Malik V. Early experience of Delamanid in extensively drug-resistant pulmonary tuberculosis. Lung India. 2023 Jan-Feb;40(1):75\u20138.","DOI":"10.4103\/lungindia.lungindia_451_22"},{"issue":"3","key":"11945_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","volume":"7","author":"F von Groote-Bidlingmaier","year":"2019","unstructured":"von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R. Efficacy and safety of Delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019;7(3):249\u201359.","journal-title":"Lancet Respir Med"},{"key":"11945_CR20","doi-asserted-by":"crossref","unstructured":"Monedero-Recuero I, Hernando-Marrupe L, S\u00e1nchez-Montalv\u00e1 A, Cox V, Tommasi M, Furin J, Chiang CY, Quelapio M, Koura KG, Tr\u00e9bucq A, Padanilam X, Dravniece G, Piubello A. QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment. Int J Tuberc Lung Dis. 2018 Oct.","DOI":"10.5588\/ijtld.18.0423"},{"issue":"6","key":"11945_CR21","doi-asserted-by":"publisher","first-page":"1800017","DOI":"10.1183\/13993003.00017-2018","volume":"51","author":"E Mohr","year":"2018","unstructured":"Mohr E, Hughes J, Reuter A, et al. Delamanid for rifampicin resistant tuberculosis: a retrospective study from South Africa[J]. Eur Respir J. 2018;51(6):1800017.","journal-title":"Eur Respir J"},{"issue":"10","key":"11945_CR22","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.5588\/ijtld.15.0541","volume":"19","author":"R Gupta","year":"2015","unstructured":"Gupta R, Geiter LJ, Hafkin J, et al. Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis[J]. Int J Tuberc Lung Dis. 2015;19(10):1261\u20132.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"11945_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40249-021-00819-2","volume":"10","author":"JT Gao","year":"2021","unstructured":"Gao JT, Du J, Wu GH, et al. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in china: focus on the safety[J]. Infect Dis Poverty. 2021;10(1):32.","journal-title":"Infect Dis Poverty"},{"issue":"2","key":"11945_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1365-2125.2012.04415.x","volume":"75","author":"RR Shah","year":"2013","unstructured":"Shah RR. Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?[J]. Br J Clin Pharmacol. 2013;75(2):347\u201358.","journal-title":"Br J Clin Pharmacol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11945-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11945-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11945-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:30:10Z","timestamp":1769171410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-11945-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["11945"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11945-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"19 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Review Committee of Hangzhou Red Cross Hospital. All patients voluntarily participated and signed an informed consent form. Ethics approval number: 2020 No. (03). It registered in ICH GCP-US Clinical Trials Registry and the registration number is NCT04421495 and date of registration was June 9, 2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}